Is Calcium Clofibrate Safe in Breastfeeding
Question
I am a breastfeeding mother and i want to know if it is safe to use Calcium Clofibrate? Is Calcium Clofibrate safe for nursing mother and child? Does Calcium Clofibrate extracts into breast milk? Does Calcium Clofibrate has any long term or short term side effects on infants? Can Calcium Clofibrate influence milk supply or can Calcium Clofibrate decrease milk supply in lactating mothers?
Calcium Clofibrate lactation summary
- DrLact safety Score for Calcium Clofibrate is 7 out of 8 which is considered Dangerous as per our analyses.
- A safety Score of 7 indicates that usage of Calcium Clofibrate may cause toxic or severe side effects in breastfed baby.
- Our study of different scientific research indicates that Calcium Clofibrate may cause moderate to high side effects or may affect milk supply in lactating mother.
- Our suggestion is to use safer alternate options rather than using Calcium Clofibrate .
- Usage of Calcium Clofibrate is in contradiction to breastfeeding hence if it is must to use Calcium Clofibrate and there is no better alternative available then breastfeeding shall be stopped permanently or temporarily.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Answer by Dr. Ru: About Calcium Clofibrate usage in lactation
Clofibrate, like other fibrates, decreases elevated blood lipids (triglycerides and cholesterol) by increasing the activity of lipases that catabolize triglyceride-rich lipoproteins and slightly decreasing cholesterol biosynthesis (Miller 1998). In general, fibrates have a discrete effect on the increase of high density lipoprotein (HDL) concentration and the reduction of low density lipoprotein (LDL). Since the last update we have not found published data in relation to breastfeeding. Its high binding to plasma proteins makes it unlikely it will pass into breast milk. Cholesterol levels in milk are very stable even in hypercholesterolemic women and are not severely affected by diet or nutritional status of the mother, suggesting that 3 is synthesized, at least in part, in the mammary gland (Lawrence 2016, p 289-90).It is not probable therefore, but it is not known if the fibrates are able to alter the lipid composition of the milk. Infants need to ingest large amounts of cholesterol, as it is critical to the proper development of the nervous system, cell membranes and is a precursor of several hormones and vitamins. Suspending the pharmacological treatment of hyperlipidemia during breastfeeding is not likely to alter the long-term outcome of the disease, especially when breastfeeding can be considered therapeutic (Lawrence 2016, p.393). It is advisable to follow a lipid-lowering diet. In case of administering a fibrate during breastfeeding it is advisable to choose those with a shorter half-life: Bezafibrate, Gemfibrozil. Due to increased mortality and other serious complications in patients treated with Clofibrate (Oliver 2012, WHO 1984), in most countries the product has been withdrawn from sale or restrictions have been imposed on its approved use. It was suggested as treatment for neonatal hyperbilirubinemia (Xiong 2012, Bourget 1995).